nodes	percent_of_prediction	percent_of_DWPC	metapath
Methylphenidate—CYP2D6—Pioglitazone—type 2 diabetes mellitus	0.0879	0.293	CbGbCtD
Methylphenidate—CYP2D6—Rosiglitazone—type 2 diabetes mellitus	0.0811	0.271	CbGbCtD
Methylphenidate—CYP2D6—Nateglinide—type 2 diabetes mellitus	0.0666	0.222	CbGbCtD
Methylphenidate—CYP2D6—Irbesartan—type 2 diabetes mellitus	0.0639	0.213	CbGbCtD
Methylphenidate—SLC6A2—sympathetic nervous system—type 2 diabetes mellitus	0.00378	0.379	CbGeAlD
Methylphenidate—SLC6A2—autonomic nervous system—type 2 diabetes mellitus	0.00254	0.255	CbGeAlD
Methylphenidate—SLC6A3—nerve—type 2 diabetes mellitus	0.00177	0.178	CbGeAlD
Methylphenidate—SLC6A2—nerve—type 2 diabetes mellitus	0.00143	0.143	CbGeAlD
Methylphenidate—SLC6A4—Circadian rythm related genes—F7—type 2 diabetes mellitus	0.000332	0.00327	CbGpPWpGaD
Methylphenidate—SLC6A3—SLC-mediated transmembrane transport—SLC5A2—type 2 diabetes mellitus	0.000331	0.00326	CbGpPWpGaD
Methylphenidate—SLC6A3—Parkinsons Disease Pathway—CASP3—type 2 diabetes mellitus	0.000327	0.00322	CbGpPWpGaD
Methylphenidate—SLC6A3—Neuronal System—ABCC8—type 2 diabetes mellitus	0.000325	0.0032	CbGpPWpGaD
Methylphenidate—CYP2D6—Cytochrome P450 - arranged by substrate type—CYP11A1—type 2 diabetes mellitus	0.000325	0.00319	CbGpPWpGaD
Methylphenidate—CYP2D6—Oxidation by Cytochrome P450—CYP11A1—type 2 diabetes mellitus	0.000321	0.00315	CbGpPWpGaD
Methylphenidate—SLC6A2—SLC-mediated transmembrane transport—HK1—type 2 diabetes mellitus	0.000318	0.00312	CbGpPWpGaD
Methylphenidate—SLC6A2—NRF2 pathway—SLC2A1—type 2 diabetes mellitus	0.000314	0.00309	CbGpPWpGaD
Methylphenidate—SLC6A4—Circadian rythm related genes—SREBF1—type 2 diabetes mellitus	0.000312	0.00307	CbGpPWpGaD
Methylphenidate—SLC6A2—Monoamine Transport—TNF—type 2 diabetes mellitus	0.000308	0.00303	CbGpPWpGaD
Methylphenidate—SLC6A3—Dopaminergic Neurogenesis—TGFB1—type 2 diabetes mellitus	0.000308	0.00303	CbGpPWpGaD
Methylphenidate—SLC6A2—SLC-mediated transmembrane transport—GCKR—type 2 diabetes mellitus	0.000307	0.00302	CbGpPWpGaD
Methylphenidate—SLC6A4—SIDS Susceptibility Pathways—GJA1—type 2 diabetes mellitus	0.000306	0.00301	CbGpPWpGaD
Methylphenidate—SLC6A4—NRF2 pathway—TGFBR2—type 2 diabetes mellitus	0.000304	0.00299	CbGpPWpGaD
Methylphenidate—SLC6A4—SIDS Susceptibility Pathways—AR—type 2 diabetes mellitus	0.000303	0.00298	CbGpPWpGaD
Methylphenidate—SLC6A2—NRF2 pathway—SLC2A4—type 2 diabetes mellitus	0.000301	0.00296	CbGpPWpGaD
Methylphenidate—CYP2D6—Melatonin metabolism and effects—CALM1—type 2 diabetes mellitus	0.0003	0.00295	CbGpPWpGaD
Methylphenidate—SLC6A4—NRF2 pathway—HMOX1—type 2 diabetes mellitus	0.0003	0.00295	CbGpPWpGaD
Methylphenidate—CYP2D6—Melatonin metabolism and effects—APOE—type 2 diabetes mellitus	0.000299	0.00294	CbGpPWpGaD
Methylphenidate—SLC6A4—Circadian rythm related genes—GHRL—type 2 diabetes mellitus	0.000296	0.00291	CbGpPWpGaD
Methylphenidate—SLC6A4—Circadian rythm related genes—ADIPOQ—type 2 diabetes mellitus	0.000287	0.00282	CbGpPWpGaD
Methylphenidate—SLC6A4—SIDS Susceptibility Pathways—PPARGC1A—type 2 diabetes mellitus	0.000286	0.00281	CbGpPWpGaD
Methylphenidate—SLC6A4—SIDS Susceptibility Pathways—GNB3—type 2 diabetes mellitus	0.000286	0.00281	CbGpPWpGaD
Methylphenidate—CYP2D6—Biological oxidations—MAT1A—type 2 diabetes mellitus	0.000285	0.0028	CbGpPWpGaD
Methylphenidate—SLC6A3—Neuronal System—GAD2—type 2 diabetes mellitus	0.000284	0.00279	CbGpPWpGaD
Methylphenidate—SLC6A4—SIDS Susceptibility Pathways—AVP—type 2 diabetes mellitus	0.000282	0.00277	CbGpPWpGaD
Methylphenidate—SLC6A3—SLC-mediated transmembrane transport—HK1—type 2 diabetes mellitus	0.000281	0.00277	CbGpPWpGaD
Methylphenidate—SLC6A4—NRF2 pathway—GSTM1—type 2 diabetes mellitus	0.00028	0.00275	CbGpPWpGaD
Methylphenidate—SLC6A3—NRF2 pathway—SLC2A1—type 2 diabetes mellitus	0.000278	0.00273	CbGpPWpGaD
Methylphenidate—SLC6A3—Monoamine Transport—TNF—type 2 diabetes mellitus	0.000273	0.00269	CbGpPWpGaD
Methylphenidate—SLC6A3—SLC-mediated transmembrane transport—GCKR—type 2 diabetes mellitus	0.000272	0.00267	CbGpPWpGaD
Methylphenidate—SLC6A4—NRF2 pathway—AGER—type 2 diabetes mellitus	0.00027	0.00265	CbGpPWpGaD
Methylphenidate—CYP2D6—kidney—type 2 diabetes mellitus	0.000268	0.0269	CbGeAlD
Methylphenidate—CYP2D6—Cytochrome P450 - arranged by substrate type—CYP2E1—type 2 diabetes mellitus	0.000268	0.00264	CbGpPWpGaD
Methylphenidate—SLC6A3—NRF2 pathway—SLC2A4—type 2 diabetes mellitus	0.000266	0.00262	CbGpPWpGaD
Methylphenidate—CYP2D6—Cytochrome P450 - arranged by substrate type—CYP1A2—type 2 diabetes mellitus	0.000265	0.00261	CbGpPWpGaD
Methylphenidate—CYP2D6—Oxidation by Cytochrome P450—CYP2E1—type 2 diabetes mellitus	0.000265	0.0026	CbGpPWpGaD
Methylphenidate—CYP2D6—Phase 1 - Functionalization of compounds—CYP11A1—type 2 diabetes mellitus	0.000263	0.00259	CbGpPWpGaD
Methylphenidate—CYP2D6—Oxidation by Cytochrome P450—CYP1A2—type 2 diabetes mellitus	0.000262	0.00257	CbGpPWpGaD
Methylphenidate—SLC6A2—NRF2 pathway—TGFBR2—type 2 diabetes mellitus	0.000262	0.00257	CbGpPWpGaD
Methylphenidate—CYP2D6—Cytochrome P450 - arranged by substrate type—CYP3A4—type 2 diabetes mellitus	0.000259	0.00254	CbGpPWpGaD
Methylphenidate—SLC6A2—NRF2 pathway—HMOX1—type 2 diabetes mellitus	0.000258	0.00254	CbGpPWpGaD
Methylphenidate—SLC6A3—Neuronal System—KCNJ11—type 2 diabetes mellitus	0.000257	0.00253	CbGpPWpGaD
Methylphenidate—SLC6A2—SLC-mediated transmembrane transport—SLC2A2—type 2 diabetes mellitus	0.000255	0.00251	CbGpPWpGaD
Methylphenidate—CYP2D6—Oxidation by Cytochrome P450—CYP3A4—type 2 diabetes mellitus	0.000255	0.00251	CbGpPWpGaD
Methylphenidate—SLC6A2—Transmembrane transport of small molecules—SLC5A4—type 2 diabetes mellitus	0.00025	0.00246	CbGpPWpGaD
Methylphenidate—SLC6A4—SIDS Susceptibility Pathways—NR3C1—type 2 diabetes mellitus	0.000245	0.00241	CbGpPWpGaD
Methylphenidate—SLC6A2—SLC-mediated transmembrane transport—GCK—type 2 diabetes mellitus	0.000244	0.0024	CbGpPWpGaD
Methylphenidate—SLC6A2—Transmembrane transport of small molecules—G6PC—type 2 diabetes mellitus	0.000242	0.00238	CbGpPWpGaD
Methylphenidate—SLC6A2—Transmembrane transport of small molecules—TRPC1—type 2 diabetes mellitus	0.000242	0.00238	CbGpPWpGaD
Methylphenidate—SLC6A2—NRF2 pathway—GSTM1—type 2 diabetes mellitus	0.00024	0.00236	CbGpPWpGaD
Methylphenidate—SLC6A3—Transmission across Chemical Synapses—SNAP25—type 2 diabetes mellitus	0.000239	0.00235	CbGpPWpGaD
Methylphenidate—SLC6A2—SLC-mediated transmembrane transport—SLC9A1—type 2 diabetes mellitus	0.000238	0.00234	CbGpPWpGaD
Methylphenidate—SLC6A4—Circadian rythm related genes—PPARGC1A—type 2 diabetes mellitus	0.000233	0.0023	CbGpPWpGaD
Methylphenidate—SLC6A2—NRF2 pathway—AGER—type 2 diabetes mellitus	0.000232	0.00228	CbGpPWpGaD
Methylphenidate—SLC6A3—NRF2 pathway—TGFBR2—type 2 diabetes mellitus	0.000232	0.00228	CbGpPWpGaD
Methylphenidate—SLC6A4—Circadian rythm related genes—AVP—type 2 diabetes mellitus	0.00023	0.00226	CbGpPWpGaD
Methylphenidate—SLC6A3—NRF2 pathway—HMOX1—type 2 diabetes mellitus	0.000229	0.00225	CbGpPWpGaD
Methylphenidate—SLC6A3—SLC-mediated transmembrane transport—SLC2A2—type 2 diabetes mellitus	0.000226	0.00222	CbGpPWpGaD
Methylphenidate—SLC6A4—Circadian rythm related genes—SIRT1—type 2 diabetes mellitus	0.000226	0.00222	CbGpPWpGaD
Methylphenidate—SLC6A4—SIDS Susceptibility Pathways—HIF1A—type 2 diabetes mellitus	0.000223	0.0022	CbGpPWpGaD
Methylphenidate—SLC6A3—Transmembrane transport of small molecules—SLC5A4—type 2 diabetes mellitus	0.000222	0.00218	CbGpPWpGaD
Methylphenidate—SLC6A2—Transmembrane transport of small molecules—PLN—type 2 diabetes mellitus	0.000221	0.00218	CbGpPWpGaD
Methylphenidate—CYP2D6—Phase 1 - Functionalization of compounds—CYP2E1—type 2 diabetes mellitus	0.000217	0.00214	CbGpPWpGaD
Methylphenidate—SLC6A3—SLC-mediated transmembrane transport—GCK—type 2 diabetes mellitus	0.000216	0.00212	CbGpPWpGaD
Methylphenidate—CYP2D6—Phase 1 - Functionalization of compounds—CYP1A2—type 2 diabetes mellitus	0.000215	0.00211	CbGpPWpGaD
Methylphenidate—SLC6A3—Transmembrane transport of small molecules—G6PC—type 2 diabetes mellitus	0.000214	0.00211	CbGpPWpGaD
Methylphenidate—SLC6A3—Transmembrane transport of small molecules—TRPC1—type 2 diabetes mellitus	0.000214	0.00211	CbGpPWpGaD
Methylphenidate—SLC6A3—NRF2 pathway—GSTM1—type 2 diabetes mellitus	0.000213	0.00209	CbGpPWpGaD
Methylphenidate—SLC6A3—SLC-mediated transmembrane transport—SLC9A1—type 2 diabetes mellitus	0.000211	0.00207	CbGpPWpGaD
Methylphenidate—CYP2D6—Phase 1 - Functionalization of compounds—CYP3A4—type 2 diabetes mellitus	0.00021	0.00206	CbGpPWpGaD
Methylphenidate—SLC6A3—NRF2 pathway—AGER—type 2 diabetes mellitus	0.000205	0.00202	CbGpPWpGaD
Methylphenidate—Malaise—Losartan—type 2 diabetes mellitus	0.000203	0.000345	CcSEcCtD
Methylphenidate—Anxiety—Irbesartan—type 2 diabetes mellitus	0.000203	0.000345	CcSEcCtD
Methylphenidate—Hypersensitivity—Glyburide—type 2 diabetes mellitus	0.000203	0.000345	CcSEcCtD
Methylphenidate—Nervous system disorder—Metformin—type 2 diabetes mellitus	0.000203	0.000345	CcSEcCtD
Methylphenidate—Thrombocytopenia—Metformin—type 2 diabetes mellitus	0.000203	0.000344	CcSEcCtD
Methylphenidate—Dyspnoea—Valsartan—type 2 diabetes mellitus	0.000203	0.000344	CcSEcCtD
Methylphenidate—Vertigo—Losartan—type 2 diabetes mellitus	0.000202	0.000344	CcSEcCtD
Methylphenidate—Unspecified disorder of skin and subcutaneous tissue—Irbesartan—type 2 diabetes mellitus	0.000202	0.000344	CcSEcCtD
Methylphenidate—Gastrointestinal pain—Gliclazide—type 2 diabetes mellitus	0.000202	0.000344	CcSEcCtD
Methylphenidate—Somnolence—Valsartan—type 2 diabetes mellitus	0.000202	0.000343	CcSEcCtD
Methylphenidate—Syncope—Losartan—type 2 diabetes mellitus	0.000202	0.000343	CcSEcCtD
Methylphenidate—Paraesthesia—Orlistat—type 2 diabetes mellitus	0.000202	0.000343	CcSEcCtD
Methylphenidate—Leukopenia—Losartan—type 2 diabetes mellitus	0.000202	0.000343	CcSEcCtD
Methylphenidate—Discomfort—Irbesartan—type 2 diabetes mellitus	0.000201	0.000342	CcSEcCtD
Methylphenidate—Skin disorder—Metformin—type 2 diabetes mellitus	0.000201	0.000342	CcSEcCtD
Methylphenidate—Immune system disorder—Ramipril—type 2 diabetes mellitus	0.0002	0.000341	CcSEcCtD
Methylphenidate—Hyperhidrosis—Metformin—type 2 diabetes mellitus	0.0002	0.00034	CcSEcCtD
Methylphenidate—Dyspepsia—Valsartan—type 2 diabetes mellitus	0.0002	0.00034	CcSEcCtD
Methylphenidate—Mediastinal disorder—Ramipril—type 2 diabetes mellitus	0.0002	0.00034	CcSEcCtD
Methylphenidate—Dizziness—Bromocriptine—type 2 diabetes mellitus	0.000199	0.000339	CcSEcCtD
Methylphenidate—Dry mouth—Irbesartan—type 2 diabetes mellitus	0.000199	0.000339	CcSEcCtD
Methylphenidate—Palpitations—Losartan—type 2 diabetes mellitus	0.000199	0.000338	CcSEcCtD
Methylphenidate—Nausea—Glimepiride—type 2 diabetes mellitus	0.000198	0.000337	CcSEcCtD
Methylphenidate—Arrhythmia—Ramipril—type 2 diabetes mellitus	0.000198	0.000337	CcSEcCtD
Methylphenidate—Loss of consciousness—Losartan—type 2 diabetes mellitus	0.000198	0.000336	CcSEcCtD
Methylphenidate—Nausea—Sitagliptin—type 2 diabetes mellitus	0.000198	0.000336	CcSEcCtD
Methylphenidate—Dyspepsia—Orlistat—type 2 diabetes mellitus	0.000198	0.000336	CcSEcCtD
Methylphenidate—Asthenia—Glyburide—type 2 diabetes mellitus	0.000198	0.000336	CcSEcCtD
Methylphenidate—SLC6A2—SLC-mediated transmembrane transport—SLC2A1—type 2 diabetes mellitus	0.000198	0.00194	CbGpPWpGaD
Methylphenidate—Decreased appetite—Valsartan—type 2 diabetes mellitus	0.000198	0.000336	CcSEcCtD
Methylphenidate—Anorexia—Metformin—type 2 diabetes mellitus	0.000197	0.000335	CcSEcCtD
Methylphenidate—SLC6A2—Transmembrane transport of small molecules—SLC30A8—type 2 diabetes mellitus	0.000197	0.00194	CbGpPWpGaD
Methylphenidate—SLC6A2—Transmembrane transport of small molecules—ABCC8—type 2 diabetes mellitus	0.000197	0.00194	CbGpPWpGaD
Methylphenidate—Cough—Losartan—type 2 diabetes mellitus	0.000197	0.000334	CcSEcCtD
Methylphenidate—Urticaria—Gliclazide—type 2 diabetes mellitus	0.000197	0.000334	CcSEcCtD
Methylphenidate—Gastrointestinal disorder—Valsartan—type 2 diabetes mellitus	0.000196	0.000333	CcSEcCtD
Methylphenidate—Alopecia—Ramipril—type 2 diabetes mellitus	0.000196	0.000333	CcSEcCtD
Methylphenidate—SLC6A3—Transmembrane transport of small molecules—PLN—type 2 diabetes mellitus	0.000196	0.00193	CbGpPWpGaD
Methylphenidate—Fatigue—Valsartan—type 2 diabetes mellitus	0.000196	0.000333	CcSEcCtD
Methylphenidate—Body temperature increased—Gliclazide—type 2 diabetes mellitus	0.000196	0.000332	CcSEcCtD
Methylphenidate—Abdominal pain—Gliclazide—type 2 diabetes mellitus	0.000196	0.000332	CcSEcCtD
Methylphenidate—Oedema—Irbesartan—type 2 diabetes mellitus	0.000195	0.000332	CcSEcCtD
Methylphenidate—Anaphylactic shock—Irbesartan—type 2 diabetes mellitus	0.000195	0.000332	CcSEcCtD
Methylphenidate—Decreased appetite—Orlistat—type 2 diabetes mellitus	0.000195	0.000332	CcSEcCtD
Methylphenidate—Pruritus—Glyburide—type 2 diabetes mellitus	0.000195	0.000331	CcSEcCtD
Methylphenidate—Mental disorder—Ramipril—type 2 diabetes mellitus	0.000194	0.00033	CcSEcCtD
Methylphenidate—Constipation—Valsartan—type 2 diabetes mellitus	0.000194	0.00033	CcSEcCtD
Methylphenidate—Infection—Irbesartan—type 2 diabetes mellitus	0.000194	0.00033	CcSEcCtD
Methylphenidate—SLC6A4—Circadian rythm related genes—FAS—type 2 diabetes mellitus	0.000194	0.00191	CbGpPWpGaD
Methylphenidate—Gastrointestinal disorder—Orlistat—type 2 diabetes mellitus	0.000194	0.00033	CcSEcCtD
Methylphenidate—Fatigue—Orlistat—type 2 diabetes mellitus	0.000194	0.000329	CcSEcCtD
Methylphenidate—Malnutrition—Ramipril—type 2 diabetes mellitus	0.000193	0.000328	CcSEcCtD
Methylphenidate—Erythema—Ramipril—type 2 diabetes mellitus	0.000193	0.000328	CcSEcCtD
Methylphenidate—Shock—Irbesartan—type 2 diabetes mellitus	0.000192	0.000327	CcSEcCtD
Methylphenidate—Pain—Orlistat—type 2 diabetes mellitus	0.000192	0.000326	CcSEcCtD
Methylphenidate—Chest pain—Losartan—type 2 diabetes mellitus	0.000192	0.000326	CcSEcCtD
Methylphenidate—Arthralgia—Losartan—type 2 diabetes mellitus	0.000192	0.000326	CcSEcCtD
Methylphenidate—Myalgia—Losartan—type 2 diabetes mellitus	0.000192	0.000326	CcSEcCtD
Methylphenidate—Vomiting—Bromocriptine—type 2 diabetes mellitus	0.000192	0.000326	CcSEcCtD
Methylphenidate—Nervous system disorder—Irbesartan—type 2 diabetes mellitus	0.000192	0.000326	CcSEcCtD
Methylphenidate—Thrombocytopenia—Irbesartan—type 2 diabetes mellitus	0.000191	0.000325	CcSEcCtD
Methylphenidate—Anxiety—Losartan—type 2 diabetes mellitus	0.000191	0.000325	CcSEcCtD
Methylphenidate—Tachycardia—Irbesartan—type 2 diabetes mellitus	0.000191	0.000324	CcSEcCtD
Methylphenidate—Rash—Bromocriptine—type 2 diabetes mellitus	0.00019	0.000323	CcSEcCtD
Methylphenidate—Dermatitis—Bromocriptine—type 2 diabetes mellitus	0.00019	0.000323	CcSEcCtD
Methylphenidate—SLC6A2—Transmembrane transport of small molecules—COX2—type 2 diabetes mellitus	0.00019	0.00187	CbGpPWpGaD
Methylphenidate—SLC6A2—Transmembrane transport of small molecules—SLC5A2—type 2 diabetes mellitus	0.00019	0.00187	CbGpPWpGaD
Methylphenidate—Skin disorder—Irbesartan—type 2 diabetes mellitus	0.00019	0.000322	CcSEcCtD
Methylphenidate—Tension—Ramipril—type 2 diabetes mellitus	0.00019	0.000322	CcSEcCtD
Methylphenidate—SLC6A2—SLC-mediated transmembrane transport—SLC2A4—type 2 diabetes mellitus	0.00019	0.00186	CbGpPWpGaD
Methylphenidate—Discomfort—Losartan—type 2 diabetes mellitus	0.000189	0.000322	CcSEcCtD
Methylphenidate—Hyperhidrosis—Irbesartan—type 2 diabetes mellitus	0.000189	0.000321	CcSEcCtD
Methylphenidate—Headache—Bromocriptine—type 2 diabetes mellitus	0.000189	0.000321	CcSEcCtD
Methylphenidate—Musculoskeletal discomfort—Metformin—type 2 diabetes mellitus	0.000189	0.00032	CcSEcCtD
Methylphenidate—Diarrhoea—Glyburide—type 2 diabetes mellitus	0.000189	0.00032	CcSEcCtD
Methylphenidate—SLC6A4—Circadian rythm related genes—PPARA—type 2 diabetes mellitus	0.000188	0.00185	CbGpPWpGaD
Methylphenidate—Nervousness—Ramipril—type 2 diabetes mellitus	0.000188	0.000319	CcSEcCtD
Methylphenidate—Dry mouth—Losartan—type 2 diabetes mellitus	0.000188	0.000319	CcSEcCtD
Methylphenidate—SLC6A2—Transmembrane transport of small molecules—NCOA6—type 2 diabetes mellitus	0.000186	0.00183	CbGpPWpGaD
Methylphenidate—Anorexia—Irbesartan—type 2 diabetes mellitus	0.000186	0.000316	CcSEcCtD
Methylphenidate—Gastrointestinal pain—Valsartan—type 2 diabetes mellitus	0.000186	0.000316	CcSEcCtD
Methylphenidate—Paraesthesia—Metformin—type 2 diabetes mellitus	0.000186	0.000316	CcSEcCtD
Methylphenidate—Muscle spasms—Ramipril—type 2 diabetes mellitus	0.000186	0.000316	CcSEcCtD
Methylphenidate—Confusional state—Losartan—type 2 diabetes mellitus	0.000185	0.000315	CcSEcCtD
Methylphenidate—Feeling abnormal—Orlistat—type 2 diabetes mellitus	0.000185	0.000315	CcSEcCtD
Methylphenidate—Dyspnoea—Metformin—type 2 diabetes mellitus	0.000185	0.000314	CcSEcCtD
Methylphenidate—Somnolence—Metformin—type 2 diabetes mellitus	0.000184	0.000313	CcSEcCtD
Methylphenidate—Oedema—Losartan—type 2 diabetes mellitus	0.000184	0.000312	CcSEcCtD
Methylphenidate—Anaphylactic shock—Losartan—type 2 diabetes mellitus	0.000184	0.000312	CcSEcCtD
Methylphenidate—Gastrointestinal pain—Orlistat—type 2 diabetes mellitus	0.000184	0.000312	CcSEcCtD
Methylphenidate—SLC6A3—Neuronal System—SNAP25—type 2 diabetes mellitus	0.000183	0.0018	CbGpPWpGaD
Methylphenidate—Infection—Losartan—type 2 diabetes mellitus	0.000183	0.00031	CcSEcCtD
Methylphenidate—Hypersensitivity—Gliclazide—type 2 diabetes mellitus	0.000182	0.00031	CcSEcCtD
Methylphenidate—Dyspepsia—Metformin—type 2 diabetes mellitus	0.000182	0.00031	CcSEcCtD
Methylphenidate—Tremor—Ramipril—type 2 diabetes mellitus	0.000181	0.000308	CcSEcCtD
Methylphenidate—Shock—Losartan—type 2 diabetes mellitus	0.000181	0.000307	CcSEcCtD
Methylphenidate—Urticaria—Valsartan—type 2 diabetes mellitus	0.000181	0.000307	CcSEcCtD
Methylphenidate—Nervous system disorder—Losartan—type 2 diabetes mellitus	0.00018	0.000306	CcSEcCtD
Methylphenidate—Thrombocytopenia—Losartan—type 2 diabetes mellitus	0.00018	0.000306	CcSEcCtD
Methylphenidate—Decreased appetite—Metformin—type 2 diabetes mellitus	0.00018	0.000306	CcSEcCtD
Methylphenidate—Abdominal pain—Valsartan—type 2 diabetes mellitus	0.00018	0.000305	CcSEcCtD
Methylphenidate—Tachycardia—Losartan—type 2 diabetes mellitus	0.000179	0.000305	CcSEcCtD
Methylphenidate—Ill-defined disorder—Ramipril—type 2 diabetes mellitus	0.000179	0.000305	CcSEcCtD
Methylphenidate—Nausea—Bromocriptine—type 2 diabetes mellitus	0.000179	0.000304	CcSEcCtD
Methylphenidate—Gastrointestinal disorder—Metformin—type 2 diabetes mellitus	0.000179	0.000304	CcSEcCtD
Methylphenidate—SLC6A3—Transmission across Chemical Synapses—GNB3—type 2 diabetes mellitus	0.000178	0.00176	CbGpPWpGaD
Methylphenidate—Fatigue—Metformin—type 2 diabetes mellitus	0.000178	0.000303	CcSEcCtD
Methylphenidate—Urticaria—Orlistat—type 2 diabetes mellitus	0.000178	0.000303	CcSEcCtD
Methylphenidate—SLC6A4—Circadian rythm related genes—LEP—type 2 diabetes mellitus	0.000178	0.00175	CbGpPWpGaD
Methylphenidate—Musculoskeletal discomfort—Irbesartan—type 2 diabetes mellitus	0.000178	0.000302	CcSEcCtD
Methylphenidate—CYP2D6—Melatonin metabolism and effects—NFKB1—type 2 diabetes mellitus	0.000178	0.00175	CbGpPWpGaD
Methylphenidate—Hyperhidrosis—Losartan—type 2 diabetes mellitus	0.000178	0.000302	CcSEcCtD
Methylphenidate—Abdominal pain—Orlistat—type 2 diabetes mellitus	0.000178	0.000302	CcSEcCtD
Methylphenidate—Body temperature increased—Orlistat—type 2 diabetes mellitus	0.000178	0.000302	CcSEcCtD
Methylphenidate—Asthenia—Gliclazide—type 2 diabetes mellitus	0.000178	0.000302	CcSEcCtD
Methylphenidate—Agitation—Ramipril—type 2 diabetes mellitus	0.000178	0.000302	CcSEcCtD
Methylphenidate—Constipation—Metformin—type 2 diabetes mellitus	0.000177	0.000301	CcSEcCtD
Methylphenidate—Angioedema—Ramipril—type 2 diabetes mellitus	0.000176	0.0003	CcSEcCtD
Methylphenidate—Paraesthesia—Irbesartan—type 2 diabetes mellitus	0.000175	0.000298	CcSEcCtD
Methylphenidate—Anorexia—Losartan—type 2 diabetes mellitus	0.000175	0.000298	CcSEcCtD
Methylphenidate—Vomiting—Glyburide—type 2 diabetes mellitus	0.000175	0.000298	CcSEcCtD
Methylphenidate—SLC6A3—SLC-mediated transmembrane transport—SLC2A1—type 2 diabetes mellitus	0.000175	0.00172	CbGpPWpGaD
Methylphenidate—Pruritus—Gliclazide—type 2 diabetes mellitus	0.000175	0.000297	CcSEcCtD
Methylphenidate—SLC6A3—Transmembrane transport of small molecules—ABCC8—type 2 diabetes mellitus	0.000175	0.00172	CbGpPWpGaD
Methylphenidate—SLC6A3—Transmembrane transport of small molecules—SLC30A8—type 2 diabetes mellitus	0.000175	0.00172	CbGpPWpGaD
Methylphenidate—Malaise—Ramipril—type 2 diabetes mellitus	0.000174	0.000296	CcSEcCtD
Methylphenidate—Dyspnoea—Irbesartan—type 2 diabetes mellitus	0.000174	0.000296	CcSEcCtD
Methylphenidate—Rash—Glyburide—type 2 diabetes mellitus	0.000174	0.000295	CcSEcCtD
Methylphenidate—Somnolence—Irbesartan—type 2 diabetes mellitus	0.000174	0.000295	CcSEcCtD
Methylphenidate—Dermatitis—Glyburide—type 2 diabetes mellitus	0.000174	0.000295	CcSEcCtD
Methylphenidate—Vertigo—Ramipril—type 2 diabetes mellitus	0.000174	0.000295	CcSEcCtD
Methylphenidate—Syncope—Ramipril—type 2 diabetes mellitus	0.000173	0.000294	CcSEcCtD
Methylphenidate—Leukopenia—Ramipril—type 2 diabetes mellitus	0.000173	0.000294	CcSEcCtD
Methylphenidate—Atropine—CYP1A2—type 2 diabetes mellitus	0.000173	0.604	CrCbGaD
Methylphenidate—Headache—Glyburide—type 2 diabetes mellitus	0.000173	0.000293	CcSEcCtD
Methylphenidate—SLC6A2—Transmembrane transport of small molecules—ATP2A3—type 2 diabetes mellitus	0.000172	0.0017	CbGpPWpGaD
Methylphenidate—Dyspepsia—Irbesartan—type 2 diabetes mellitus	0.000172	0.000292	CcSEcCtD
Methylphenidate—Palpitations—Ramipril—type 2 diabetes mellitus	0.000171	0.00029	CcSEcCtD
Methylphenidate—Feeling abnormal—Metformin—type 2 diabetes mellitus	0.000171	0.00029	CcSEcCtD
Methylphenidate—Decreased appetite—Irbesartan—type 2 diabetes mellitus	0.00017	0.000289	CcSEcCtD
Methylphenidate—Loss of consciousness—Ramipril—type 2 diabetes mellitus	0.00017	0.000288	CcSEcCtD
Methylphenidate—CYP2D6—liver—type 2 diabetes mellitus	0.00017	0.017	CbGeAlD
Methylphenidate—Diarrhoea—Gliclazide—type 2 diabetes mellitus	0.000169	0.000288	CcSEcCtD
Methylphenidate—Gastrointestinal pain—Metformin—type 2 diabetes mellitus	0.000169	0.000288	CcSEcCtD
Methylphenidate—Gastrointestinal disorder—Irbesartan—type 2 diabetes mellitus	0.000169	0.000287	CcSEcCtD
Methylphenidate—Cough—Ramipril—type 2 diabetes mellitus	0.000169	0.000286	CcSEcCtD
Methylphenidate—Fatigue—Irbesartan—type 2 diabetes mellitus	0.000168	0.000286	CcSEcCtD
Methylphenidate—SLC6A3—Transmembrane transport of small molecules—COX2—type 2 diabetes mellitus	0.000168	0.00165	CbGpPWpGaD
Methylphenidate—SLC6A3—Transmembrane transport of small molecules—SLC5A2—type 2 diabetes mellitus	0.000168	0.00165	CbGpPWpGaD
Methylphenidate—SLC6A3—SLC-mediated transmembrane transport—SLC2A4—type 2 diabetes mellitus	0.000168	0.00165	CbGpPWpGaD
Methylphenidate—Musculoskeletal discomfort—Losartan—type 2 diabetes mellitus	0.000167	0.000285	CcSEcCtD
Methylphenidate—Hypersensitivity—Valsartan—type 2 diabetes mellitus	0.000167	0.000285	CcSEcCtD
Methylphenidate—Convulsion—Ramipril—type 2 diabetes mellitus	0.000167	0.000284	CcSEcCtD
Methylphenidate—Pain—Irbesartan—type 2 diabetes mellitus	0.000167	0.000284	CcSEcCtD
Methylphenidate—Constipation—Irbesartan—type 2 diabetes mellitus	0.000167	0.000284	CcSEcCtD
Methylphenidate—Insomnia—Losartan—type 2 diabetes mellitus	0.000166	0.000283	CcSEcCtD
Methylphenidate—SLC6A4—Circadian rythm related genes—NOS2—type 2 diabetes mellitus	0.000166	0.00163	CbGpPWpGaD
Methylphenidate—Hypersensitivity—Orlistat—type 2 diabetes mellitus	0.000165	0.000281	CcSEcCtD
Methylphenidate—SLC6A3—Transmembrane transport of small molecules—NCOA6—type 2 diabetes mellitus	0.000165	0.00162	CbGpPWpGaD
Methylphenidate—Paraesthesia—Losartan—type 2 diabetes mellitus	0.000165	0.000281	CcSEcCtD
Methylphenidate—Urticaria—Metformin—type 2 diabetes mellitus	0.000164	0.000279	CcSEcCtD
Methylphenidate—Chest pain—Ramipril—type 2 diabetes mellitus	0.000164	0.000279	CcSEcCtD
Methylphenidate—Myalgia—Ramipril—type 2 diabetes mellitus	0.000164	0.000279	CcSEcCtD
Methylphenidate—Arthralgia—Ramipril—type 2 diabetes mellitus	0.000164	0.000279	CcSEcCtD
Methylphenidate—Dyspnoea—Losartan—type 2 diabetes mellitus	0.000164	0.000279	CcSEcCtD
Methylphenidate—Anxiety—Ramipril—type 2 diabetes mellitus	0.000164	0.000278	CcSEcCtD
Methylphenidate—Nausea—Glyburide—type 2 diabetes mellitus	0.000164	0.000278	CcSEcCtD
Methylphenidate—Abdominal pain—Metformin—type 2 diabetes mellitus	0.000164	0.000278	CcSEcCtD
Methylphenidate—Dizziness—Gliclazide—type 2 diabetes mellitus	0.000164	0.000278	CcSEcCtD
Methylphenidate—Somnolence—Losartan—type 2 diabetes mellitus	0.000163	0.000278	CcSEcCtD
Methylphenidate—Unspecified disorder of skin and subcutaneous tissue—Ramipril—type 2 diabetes mellitus	0.000163	0.000278	CcSEcCtD
Methylphenidate—Asthenia—Valsartan—type 2 diabetes mellitus	0.000163	0.000277	CcSEcCtD
Methylphenidate—Discomfort—Ramipril—type 2 diabetes mellitus	0.000162	0.000276	CcSEcCtD
Methylphenidate—Dyspepsia—Losartan—type 2 diabetes mellitus	0.000162	0.000275	CcSEcCtD
Methylphenidate—SLC6A2—Transmembrane transport of small molecules—HK1—type 2 diabetes mellitus	0.000161	0.00159	CbGpPWpGaD
Methylphenidate—Asthenia—Orlistat—type 2 diabetes mellitus	0.000161	0.000274	CcSEcCtD
Methylphenidate—SLC6A2—SLC-mediated transmembrane transport—AVP—type 2 diabetes mellitus	0.000161	0.00159	CbGpPWpGaD
Methylphenidate—Feeling abnormal—Irbesartan—type 2 diabetes mellitus	0.000161	0.000274	CcSEcCtD
Methylphenidate—Pruritus—Valsartan—type 2 diabetes mellitus	0.000161	0.000273	CcSEcCtD
Methylphenidate—Dry mouth—Ramipril—type 2 diabetes mellitus	0.000161	0.000273	CcSEcCtD
Methylphenidate—Decreased appetite—Losartan—type 2 diabetes mellitus	0.00016	0.000272	CcSEcCtD
Methylphenidate—Gastrointestinal pain—Irbesartan—type 2 diabetes mellitus	0.00016	0.000271	CcSEcCtD
Methylphenidate—SLC6A3—Transmission across Chemical Synapses—ADCY5—type 2 diabetes mellitus	0.000159	0.00156	CbGpPWpGaD
Methylphenidate—Confusional state—Ramipril—type 2 diabetes mellitus	0.000159	0.00027	CcSEcCtD
Methylphenidate—Pruritus—Orlistat—type 2 diabetes mellitus	0.000159	0.00027	CcSEcCtD
Methylphenidate—Fatigue—Losartan—type 2 diabetes mellitus	0.000159	0.000269	CcSEcCtD
Methylphenidate—Anaphylactic shock—Ramipril—type 2 diabetes mellitus	0.000158	0.000268	CcSEcCtD
Methylphenidate—Oedema—Ramipril—type 2 diabetes mellitus	0.000158	0.000268	CcSEcCtD
Methylphenidate—Vomiting—Gliclazide—type 2 diabetes mellitus	0.000157	0.000267	CcSEcCtD
Methylphenidate—Constipation—Losartan—type 2 diabetes mellitus	0.000157	0.000267	CcSEcCtD
Methylphenidate—Pain—Losartan—type 2 diabetes mellitus	0.000157	0.000267	CcSEcCtD
Methylphenidate—Rash—Gliclazide—type 2 diabetes mellitus	0.000156	0.000265	CcSEcCtD
Methylphenidate—SLC6A2—Transmembrane transport of small molecules—GCKR—type 2 diabetes mellitus	0.000156	0.00153	CbGpPWpGaD
Methylphenidate—Dermatitis—Gliclazide—type 2 diabetes mellitus	0.000156	0.000265	CcSEcCtD
Methylphenidate—Diarrhoea—Valsartan—type 2 diabetes mellitus	0.000156	0.000264	CcSEcCtD
Methylphenidate—Urticaria—Irbesartan—type 2 diabetes mellitus	0.000155	0.000264	CcSEcCtD
Methylphenidate—SLC6A4—Circadian rythm related genes—PPARG—type 2 diabetes mellitus	0.000155	0.00153	CbGpPWpGaD
Methylphenidate—Shock—Ramipril—type 2 diabetes mellitus	0.000155	0.000264	CcSEcCtD
Methylphenidate—Headache—Gliclazide—type 2 diabetes mellitus	0.000155	0.000263	CcSEcCtD
Methylphenidate—Nervous system disorder—Ramipril—type 2 diabetes mellitus	0.000155	0.000263	CcSEcCtD
Methylphenidate—Abdominal pain—Irbesartan—type 2 diabetes mellitus	0.000154	0.000262	CcSEcCtD
Methylphenidate—Body temperature increased—Irbesartan—type 2 diabetes mellitus	0.000154	0.000262	CcSEcCtD
Methylphenidate—Thrombocytopenia—Ramipril—type 2 diabetes mellitus	0.000154	0.000262	CcSEcCtD
Methylphenidate—Tachycardia—Ramipril—type 2 diabetes mellitus	0.000154	0.000261	CcSEcCtD
Methylphenidate—Diarrhoea—Orlistat—type 2 diabetes mellitus	0.000154	0.000261	CcSEcCtD
Methylphenidate—Skin disorder—Ramipril—type 2 diabetes mellitus	0.000153	0.00026	CcSEcCtD
Methylphenidate—SLC6A3—Transmembrane transport of small molecules—ATP2A3—type 2 diabetes mellitus	0.000153	0.0015	CbGpPWpGaD
Methylphenidate—Hyperhidrosis—Ramipril—type 2 diabetes mellitus	0.000152	0.000259	CcSEcCtD
Methylphenidate—Feeling abnormal—Losartan—type 2 diabetes mellitus	0.000151	0.000257	CcSEcCtD
Methylphenidate—Gastrointestinal pain—Losartan—type 2 diabetes mellitus	0.00015	0.000255	CcSEcCtD
Methylphenidate—Dizziness—Valsartan—type 2 diabetes mellitus	0.00015	0.000255	CcSEcCtD
Methylphenidate—Anorexia—Ramipril—type 2 diabetes mellitus	0.00015	0.000255	CcSEcCtD
Methylphenidate—SLC6A2—Transmembrane transport of small molecules—ABCC2—type 2 diabetes mellitus	0.000149	0.00147	CbGpPWpGaD
Methylphenidate—Dizziness—Orlistat—type 2 diabetes mellitus	0.000149	0.000252	CcSEcCtD
Methylphenidate—Asthenia—Metformin—type 2 diabetes mellitus	0.000149	0.000252	CcSEcCtD
Methylphenidate—Nausea—Gliclazide—type 2 diabetes mellitus	0.000147	0.00025	CcSEcCtD
Methylphenidate—Pruritus—Metformin—type 2 diabetes mellitus	0.000146	0.000249	CcSEcCtD
Methylphenidate—Urticaria—Losartan—type 2 diabetes mellitus	0.000146	0.000248	CcSEcCtD
Methylphenidate—Body temperature increased—Losartan—type 2 diabetes mellitus	0.000145	0.000247	CcSEcCtD
Methylphenidate—Abdominal pain—Losartan—type 2 diabetes mellitus	0.000145	0.000247	CcSEcCtD
Methylphenidate—Vomiting—Valsartan—type 2 diabetes mellitus	0.000145	0.000246	CcSEcCtD
Methylphenidate—CYP2D6—Biological oxidations—MTR—type 2 diabetes mellitus	0.000144	0.00142	CbGpPWpGaD
Methylphenidate—Hypersensitivity—Irbesartan—type 2 diabetes mellitus	0.000144	0.000245	CcSEcCtD
Methylphenidate—Musculoskeletal discomfort—Ramipril—type 2 diabetes mellitus	0.000144	0.000244	CcSEcCtD
Methylphenidate—Rash—Valsartan—type 2 diabetes mellitus	0.000143	0.000244	CcSEcCtD
Methylphenidate—Dermatitis—Valsartan—type 2 diabetes mellitus	0.000143	0.000243	CcSEcCtD
Methylphenidate—SLC6A3—Transmembrane transport of small molecules—HK1—type 2 diabetes mellitus	0.000143	0.00141	CbGpPWpGaD
Methylphenidate—Vomiting—Orlistat—type 2 diabetes mellitus	0.000143	0.000243	CcSEcCtD
Methylphenidate—SLC6A3—SLC-mediated transmembrane transport—AVP—type 2 diabetes mellitus	0.000143	0.0014	CbGpPWpGaD
Methylphenidate—Insomnia—Ramipril—type 2 diabetes mellitus	0.000143	0.000242	CcSEcCtD
Methylphenidate—Headache—Valsartan—type 2 diabetes mellitus	0.000142	0.000242	CcSEcCtD
Methylphenidate—Diarrhoea—Metformin—type 2 diabetes mellitus	0.000142	0.000241	CcSEcCtD
Methylphenidate—Rash—Orlistat—type 2 diabetes mellitus	0.000142	0.000241	CcSEcCtD
Methylphenidate—Paraesthesia—Ramipril—type 2 diabetes mellitus	0.000142	0.000241	CcSEcCtD
Methylphenidate—Dermatitis—Orlistat—type 2 diabetes mellitus	0.000141	0.00024	CcSEcCtD
Methylphenidate—Headache—Orlistat—type 2 diabetes mellitus	0.000141	0.000239	CcSEcCtD
Methylphenidate—Dyspnoea—Ramipril—type 2 diabetes mellitus	0.000141	0.000239	CcSEcCtD
Methylphenidate—Asthenia—Irbesartan—type 2 diabetes mellitus	0.00014	0.000238	CcSEcCtD
Methylphenidate—Somnolence—Ramipril—type 2 diabetes mellitus	0.00014	0.000238	CcSEcCtD
Methylphenidate—CYP2D6—Biological oxidations—CYP11A1—type 2 diabetes mellitus	0.00014	0.00138	CbGpPWpGaD
Methylphenidate—SLC6A4—Circadian rythm related genes—SERPINE1—type 2 diabetes mellitus	0.00014	0.00137	CbGpPWpGaD
Methylphenidate—Dyspepsia—Ramipril—type 2 diabetes mellitus	0.000139	0.000236	CcSEcCtD
Methylphenidate—SLC6A4—SIDS Susceptibility Pathways—CASP3—type 2 diabetes mellitus	0.000139	0.00136	CbGpPWpGaD
Methylphenidate—Pruritus—Irbesartan—type 2 diabetes mellitus	0.000138	0.000235	CcSEcCtD
Methylphenidate—SLC6A3—Transmembrane transport of small molecules—GCKR—type 2 diabetes mellitus	0.000138	0.00136	CbGpPWpGaD
Methylphenidate—CYP2D6—Metapathway biotransformation—CYP11A1—type 2 diabetes mellitus	0.000138	0.00136	CbGpPWpGaD
Methylphenidate—Decreased appetite—Ramipril—type 2 diabetes mellitus	0.000137	0.000233	CcSEcCtD
Methylphenidate—Dizziness—Metformin—type 2 diabetes mellitus	0.000137	0.000233	CcSEcCtD
Methylphenidate—SLC6A3—Neuronal System—GNB3—type 2 diabetes mellitus	0.000137	0.00135	CbGpPWpGaD
Methylphenidate—SLC6A3—Transmission across Chemical Synapses—CALM1—type 2 diabetes mellitus	0.000137	0.00134	CbGpPWpGaD
Methylphenidate—Gastrointestinal disorder—Ramipril—type 2 diabetes mellitus	0.000136	0.000231	CcSEcCtD
Methylphenidate—Fatigue—Ramipril—type 2 diabetes mellitus	0.000136	0.000231	CcSEcCtD
Methylphenidate—Hypersensitivity—Losartan—type 2 diabetes mellitus	0.000135	0.00023	CcSEcCtD
Methylphenidate—Nausea—Valsartan—type 2 diabetes mellitus	0.000135	0.000229	CcSEcCtD
Methylphenidate—Constipation—Ramipril—type 2 diabetes mellitus	0.000135	0.000229	CcSEcCtD
Methylphenidate—Diarrhoea—Irbesartan—type 2 diabetes mellitus	0.000134	0.000227	CcSEcCtD
Methylphenidate—Nausea—Orlistat—type 2 diabetes mellitus	0.000133	0.000227	CcSEcCtD
Methylphenidate—SLC6A3—Transmembrane transport of small molecules—ABCC2—type 2 diabetes mellitus	0.000132	0.0013	CbGpPWpGaD
Methylphenidate—Asthenia—Losartan—type 2 diabetes mellitus	0.000132	0.000224	CcSEcCtD
Methylphenidate—Vomiting—Metformin—type 2 diabetes mellitus	0.000132	0.000224	CcSEcCtD
Methylphenidate—Rash—Metformin—type 2 diabetes mellitus	0.000131	0.000222	CcSEcCtD
Methylphenidate—Dermatitis—Metformin—type 2 diabetes mellitus	0.00013	0.000222	CcSEcCtD
Methylphenidate—Pruritus—Losartan—type 2 diabetes mellitus	0.00013	0.000221	CcSEcCtD
Methylphenidate—Feeling abnormal—Ramipril—type 2 diabetes mellitus	0.00013	0.000221	CcSEcCtD
Methylphenidate—SLC6A4—SIDS Susceptibility Pathways—NFKB1—type 2 diabetes mellitus	0.00013	0.00128	CbGpPWpGaD
Methylphenidate—SLC6A2—Transmembrane transport of small molecules—SLC2A2—type 2 diabetes mellitus	0.00013	0.00128	CbGpPWpGaD
Methylphenidate—Headache—Metformin—type 2 diabetes mellitus	0.00013	0.00022	CcSEcCtD
Methylphenidate—Dizziness—Irbesartan—type 2 diabetes mellitus	0.000129	0.00022	CcSEcCtD
Methylphenidate—Gastrointestinal pain—Ramipril—type 2 diabetes mellitus	0.000129	0.000219	CcSEcCtD
Methylphenidate—SLC6A3—Transmission across Chemical Synapses—PRKCB—type 2 diabetes mellitus	0.000128	0.00126	CbGpPWpGaD
Methylphenidate—Diarrhoea—Losartan—type 2 diabetes mellitus	0.000126	0.000214	CcSEcCtD
Methylphenidate—Urticaria—Ramipril—type 2 diabetes mellitus	0.000125	0.000213	CcSEcCtD
Methylphenidate—Body temperature increased—Ramipril—type 2 diabetes mellitus	0.000125	0.000212	CcSEcCtD
Methylphenidate—Abdominal pain—Ramipril—type 2 diabetes mellitus	0.000125	0.000212	CcSEcCtD
Methylphenidate—Vomiting—Irbesartan—type 2 diabetes mellitus	0.000124	0.000211	CcSEcCtD
Methylphenidate—SLC6A2—Transmembrane transport of small molecules—ATP2A2—type 2 diabetes mellitus	0.000124	0.00122	CbGpPWpGaD
Methylphenidate—SLC6A2—Transmembrane transport of small molecules—GCK—type 2 diabetes mellitus	0.000124	0.00122	CbGpPWpGaD
Methylphenidate—Rash—Irbesartan—type 2 diabetes mellitus	0.000123	0.000209	CcSEcCtD
Methylphenidate—Dermatitis—Irbesartan—type 2 diabetes mellitus	0.000123	0.000209	CcSEcCtD
Methylphenidate—Nausea—Metformin—type 2 diabetes mellitus	0.000123	0.000209	CcSEcCtD
Methylphenidate—Headache—Irbesartan—type 2 diabetes mellitus	0.000122	0.000208	CcSEcCtD
Methylphenidate—SLC6A3—Neuronal System—ADCY5—type 2 diabetes mellitus	0.000122	0.0012	CbGpPWpGaD
Methylphenidate—Dizziness—Losartan—type 2 diabetes mellitus	0.000122	0.000207	CcSEcCtD
Methylphenidate—SLC6A2—Transmembrane transport of small molecules—SLC9A1—type 2 diabetes mellitus	0.000121	0.00119	CbGpPWpGaD
Methylphenidate—SLC6A2—Transmembrane transport of small molecules—TRPC6—type 2 diabetes mellitus	0.00012	0.00118	CbGpPWpGaD
Methylphenidate—SLC6A2—Transmembrane transport of small molecules—CETP—type 2 diabetes mellitus	0.000119	0.00118	CbGpPWpGaD
Methylphenidate—SLC6A4—SIDS Susceptibility Pathways—VEGFA—type 2 diabetes mellitus	0.000118	0.00116	CbGpPWpGaD
Methylphenidate—Vomiting—Losartan—type 2 diabetes mellitus	0.000117	0.000199	CcSEcCtD
Methylphenidate—Hypersensitivity—Ramipril—type 2 diabetes mellitus	0.000116	0.000197	CcSEcCtD
Methylphenidate—Nausea—Irbesartan—type 2 diabetes mellitus	0.000116	0.000197	CcSEcCtD
Methylphenidate—Rash—Losartan—type 2 diabetes mellitus	0.000116	0.000197	CcSEcCtD
Methylphenidate—Dermatitis—Losartan—type 2 diabetes mellitus	0.000116	0.000197	CcSEcCtD
Methylphenidate—CYP2D6—Biological oxidations—CYP2E1—type 2 diabetes mellitus	0.000115	0.00114	CbGpPWpGaD
Methylphenidate—Headache—Losartan—type 2 diabetes mellitus	0.000115	0.000196	CcSEcCtD
Methylphenidate—SLC6A3—Transmembrane transport of small molecules—SLC2A2—type 2 diabetes mellitus	0.000115	0.00113	CbGpPWpGaD
Methylphenidate—CYP2D6—Biological oxidations—CYP1A2—type 2 diabetes mellitus	0.000114	0.00112	CbGpPWpGaD
Methylphenidate—SLC6A4—NRF2 pathway—TGFB1—type 2 diabetes mellitus	0.000114	0.00112	CbGpPWpGaD
Methylphenidate—CYP2D6—Metapathway biotransformation—CYP2E1—type 2 diabetes mellitus	0.000114	0.00112	CbGpPWpGaD
Methylphenidate—Ipratropium bromide—CYP3A4—type 2 diabetes mellitus	0.000113	0.396	CrCbGaD
Methylphenidate—Asthenia—Ramipril—type 2 diabetes mellitus	0.000113	0.000192	CcSEcCtD
Methylphenidate—CYP2D6—Metapathway biotransformation—CYP1A2—type 2 diabetes mellitus	0.000113	0.00111	CbGpPWpGaD
Methylphenidate—Pruritus—Ramipril—type 2 diabetes mellitus	0.000112	0.00019	CcSEcCtD
Methylphenidate—CYP2D6—Biological oxidations—CYP3A4—type 2 diabetes mellitus	0.000111	0.0011	CbGpPWpGaD
Methylphenidate—CYP2D6—Metapathway biotransformation—CYP3A4—type 2 diabetes mellitus	0.00011	0.00108	CbGpPWpGaD
Methylphenidate—SLC6A3—Transmembrane transport of small molecules—ATP2A2—type 2 diabetes mellitus	0.00011	0.00108	CbGpPWpGaD
Methylphenidate—SLC6A3—Transmembrane transport of small molecules—GCK—type 2 diabetes mellitus	0.00011	0.00108	CbGpPWpGaD
Methylphenidate—Nausea—Losartan—type 2 diabetes mellitus	0.000109	0.000186	CcSEcCtD
Methylphenidate—Diarrhoea—Ramipril—type 2 diabetes mellitus	0.000108	0.000183	CcSEcCtD
Methylphenidate—SLC6A3—Transmembrane transport of small molecules—SLC9A1—type 2 diabetes mellitus	0.000107	0.00105	CbGpPWpGaD
Methylphenidate—SLC6A3—Transmembrane transport of small molecules—TRPC6—type 2 diabetes mellitus	0.000106	0.00105	CbGpPWpGaD
Methylphenidate—SLC6A3—Transmembrane transport of small molecules—CETP—type 2 diabetes mellitus	0.000106	0.00104	CbGpPWpGaD
Methylphenidate—SLC6A2—Transmembrane transport of small molecules—PLAT—type 2 diabetes mellitus	0.000105	0.00104	CbGpPWpGaD
Methylphenidate—SLC6A3—Neuronal System—CALM1—type 2 diabetes mellitus	0.000105	0.00103	CbGpPWpGaD
Methylphenidate—Dizziness—Ramipril—type 2 diabetes mellitus	0.000104	0.000177	CcSEcCtD
Methylphenidate—SLC6A4—SIDS Susceptibility Pathways—TNF—type 2 diabetes mellitus	0.000101	0.000993	CbGpPWpGaD
Methylphenidate—SLC6A2—Transmembrane transport of small molecules—SLC2A1—type 2 diabetes mellitus	0.0001	0.000988	CbGpPWpGaD
Methylphenidate—Vomiting—Ramipril—type 2 diabetes mellitus	0.0001	0.00017	CcSEcCtD
Methylphenidate—Rash—Ramipril—type 2 diabetes mellitus	9.94e-05	0.000169	CcSEcCtD
Methylphenidate—Dermatitis—Ramipril—type 2 diabetes mellitus	9.93e-05	0.000169	CcSEcCtD
Methylphenidate—Headache—Ramipril—type 2 diabetes mellitus	9.88e-05	0.000168	CcSEcCtD
Methylphenidate—SLC6A3—Neuronal System—PRKCB—type 2 diabetes mellitus	9.84e-05	0.000968	CbGpPWpGaD
Methylphenidate—SLC6A2—NRF2 pathway—TGFB1—type 2 diabetes mellitus	9.8e-05	0.000964	CbGpPWpGaD
Methylphenidate—SLC6A2—SLC-mediated transmembrane transport—ALB—type 2 diabetes mellitus	9.76e-05	0.00096	CbGpPWpGaD
Methylphenidate—SLC6A2—Transmembrane transport of small molecules—SLC2A4—type 2 diabetes mellitus	9.63e-05	0.000947	CbGpPWpGaD
Methylphenidate—Nausea—Ramipril—type 2 diabetes mellitus	9.36e-05	0.000159	CcSEcCtD
Methylphenidate—SLC6A3—Transmembrane transport of small molecules—PLAT—type 2 diabetes mellitus	9.33e-05	0.000918	CbGpPWpGaD
Methylphenidate—SLC6A3—Transmembrane transport of small molecules—SLC2A1—type 2 diabetes mellitus	8.9e-05	0.000875	CbGpPWpGaD
Methylphenidate—CYP2D6—Biological oxidations—GSTM1—type 2 diabetes mellitus	8.75e-05	0.000861	CbGpPWpGaD
Methylphenidate—SLC6A3—NRF2 pathway—TGFB1—type 2 diabetes mellitus	8.68e-05	0.000854	CbGpPWpGaD
Methylphenidate—SLC6A3—SLC-mediated transmembrane transport—ALB—type 2 diabetes mellitus	8.65e-05	0.000851	CbGpPWpGaD
Methylphenidate—CYP2D6—Metapathway biotransformation—GSTM1—type 2 diabetes mellitus	8.63e-05	0.000849	CbGpPWpGaD
Methylphenidate—SLC6A3—Transmembrane transport of small molecules—SLC2A4—type 2 diabetes mellitus	8.53e-05	0.000839	CbGpPWpGaD
Methylphenidate—SLC6A2—Transmembrane transport of small molecules—GNB3—type 2 diabetes mellitus	8.3e-05	0.000816	CbGpPWpGaD
Methylphenidate—SLC6A2—Transmembrane transport of small molecules—HMOX1—type 2 diabetes mellitus	8.26e-05	0.000813	CbGpPWpGaD
Methylphenidate—SLC6A2—Transmembrane transport of small molecules—AVP—type 2 diabetes mellitus	8.19e-05	0.000805	CbGpPWpGaD
Methylphenidate—SLC6A4—SIDS Susceptibility Pathways—IL6—type 2 diabetes mellitus	8.14e-05	0.000801	CbGpPWpGaD
Methylphenidate—SLC6A2—Transmembrane transport of small molecules—APOB—type 2 diabetes mellitus	7.91e-05	0.000778	CbGpPWpGaD
Methylphenidate—SLC6A2—Transmembrane transport of small molecules—ADCY5—type 2 diabetes mellitus	7.4e-05	0.000728	CbGpPWpGaD
Methylphenidate—SLC6A3—Transmembrane transport of small molecules—GNB3—type 2 diabetes mellitus	7.35e-05	0.000723	CbGpPWpGaD
Methylphenidate—SLC6A3—Transmembrane transport of small molecules—HMOX1—type 2 diabetes mellitus	7.32e-05	0.00072	CbGpPWpGaD
Methylphenidate—SLC6A3—Transmembrane transport of small molecules—AVP—type 2 diabetes mellitus	7.25e-05	0.000714	CbGpPWpGaD
Methylphenidate—SLC6A3—Transmembrane transport of small molecules—APOB—type 2 diabetes mellitus	7.01e-05	0.00069	CbGpPWpGaD
Methylphenidate—SLC6A2—Transmembrane transport of small molecules—PPARA—type 2 diabetes mellitus	6.68e-05	0.000657	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—BHMT—type 2 diabetes mellitus	6.67e-05	0.000656	CbGpPWpGaD
Methylphenidate—SLC6A4—Circadian rythm related genes—IL6—type 2 diabetes mellitus	6.65e-05	0.000654	CbGpPWpGaD
Methylphenidate—SLC6A3—Transmembrane transport of small molecules—ADCY5—type 2 diabetes mellitus	6.55e-05	0.000645	CbGpPWpGaD
Methylphenidate—SLC6A2—Transmembrane transport of small molecules—APOA1—type 2 diabetes mellitus	6.26e-05	0.000616	CbGpPWpGaD
Methylphenidate—SLC6A3—Transmembrane transport of small molecules—PPARA—type 2 diabetes mellitus	5.91e-05	0.000582	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—PTGDS—type 2 diabetes mellitus	5.83e-05	0.000574	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—AANAT—type 2 diabetes mellitus	5.83e-05	0.000574	CbGpPWpGaD
Methylphenidate—SLC6A3—Transmembrane transport of small molecules—APOA1—type 2 diabetes mellitus	5.55e-05	0.000546	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—CDO1—type 2 diabetes mellitus	5.53e-05	0.000544	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—GPD2—type 2 diabetes mellitus	5.53e-05	0.000544	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—AK1—type 2 diabetes mellitus	5.27e-05	0.000519	CbGpPWpGaD
Methylphenidate—SLC6A2—Transmembrane transport of small molecules—ALB—type 2 diabetes mellitus	4.96e-05	0.000488	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—MAT1A—type 2 diabetes mellitus	4.87e-05	0.000479	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—SLC5A4—type 2 diabetes mellitus	4.87e-05	0.000479	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—HBA2—type 2 diabetes mellitus	4.7e-05	0.000462	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—G6PC—type 2 diabetes mellitus	4.7e-05	0.000462	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—ND1—type 2 diabetes mellitus	4.7e-05	0.000462	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—PPP1R3C—type 2 diabetes mellitus	4.7e-05	0.000462	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—ENPP1—type 2 diabetes mellitus	4.7e-05	0.000462	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—GCGR—type 2 diabetes mellitus	4.55e-05	0.000448	CbGpPWpGaD
Methylphenidate—SLC6A3—Transmembrane transport of small molecules—ALB—type 2 diabetes mellitus	4.39e-05	0.000432	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—OXCT1—type 2 diabetes mellitus	4.3e-05	0.000423	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—CYTB—type 2 diabetes mellitus	4.3e-05	0.000423	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—SRD5A1—type 2 diabetes mellitus	4.19e-05	0.000412	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—HSD17B3—type 2 diabetes mellitus	4e-05	0.000393	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—STAR—type 2 diabetes mellitus	4e-05	0.000393	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—ACACA—type 2 diabetes mellitus	4e-05	0.000393	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—ABCC8—type 2 diabetes mellitus	3.83e-05	0.000377	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—CBS—type 2 diabetes mellitus	3.83e-05	0.000377	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—COX2—type 2 diabetes mellitus	3.69e-05	0.000363	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—SLC5A2—type 2 diabetes mellitus	3.69e-05	0.000363	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—NCOA6—type 2 diabetes mellitus	3.62e-05	0.000357	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—HSD11B1—type 2 diabetes mellitus	3.56e-05	0.00035	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—UCP2—type 2 diabetes mellitus	3.56e-05	0.00035	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—UCP3—type 2 diabetes mellitus	3.56e-05	0.00035	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—PCK1—type 2 diabetes mellitus	3.35e-05	0.00033	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—HK1—type 2 diabetes mellitus	3.14e-05	0.000309	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—HSD3B2—type 2 diabetes mellitus	3.03e-05	0.000298	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—GCKR—type 2 diabetes mellitus	3.03e-05	0.000298	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—KCNJ11—type 2 diabetes mellitus	3.03e-05	0.000298	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—LPA—type 2 diabetes mellitus	3.03e-05	0.000298	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—ALDOB—type 2 diabetes mellitus	2.9e-05	0.000286	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—GLP1R—type 2 diabetes mellitus	2.7e-05	0.000266	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—SLC2A2—type 2 diabetes mellitus	2.52e-05	0.000248	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—CPT1A—type 2 diabetes mellitus	2.47e-05	0.000243	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—MTR—type 2 diabetes mellitus	2.47e-05	0.000243	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—NAMPT—type 2 diabetes mellitus	2.42e-05	0.000238	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—GCK—type 2 diabetes mellitus	2.41e-05	0.000237	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—LIPC—type 2 diabetes mellitus	2.41e-05	0.000237	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—HBA1—type 2 diabetes mellitus	2.41e-05	0.000237	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—CYP11A1—type 2 diabetes mellitus	2.39e-05	0.000235	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—SLC9A1—type 2 diabetes mellitus	2.35e-05	0.000231	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—CETP—type 2 diabetes mellitus	2.32e-05	0.000228	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—PSMD6—type 2 diabetes mellitus	2.16e-05	0.000212	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—SREBF1—type 2 diabetes mellitus	2.16e-05	0.000212	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—SNAP25—type 2 diabetes mellitus	2.16e-05	0.000212	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—CTGF—type 2 diabetes mellitus	2.12e-05	0.000208	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—HMGCR—type 2 diabetes mellitus	2.1e-05	0.000207	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—ADRA2A—type 2 diabetes mellitus	2.06e-05	0.000202	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—CYP2E1—type 2 diabetes mellitus	1.97e-05	0.000194	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—SLC2A1—type 2 diabetes mellitus	1.95e-05	0.000192	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—CYP1A2—type 2 diabetes mellitus	1.95e-05	0.000192	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—CYP3A4—type 2 diabetes mellitus	1.9e-05	0.000187	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—SLC2A4—type 2 diabetes mellitus	1.87e-05	0.000184	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—GCG—type 2 diabetes mellitus	1.87e-05	0.000184	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—GNB3—type 2 diabetes mellitus	1.61e-05	0.000159	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—PPARGC1A—type 2 diabetes mellitus	1.61e-05	0.000159	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—HMOX1—type 2 diabetes mellitus	1.61e-05	0.000158	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—CAT—type 2 diabetes mellitus	1.58e-05	0.000156	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—APOB—type 2 diabetes mellitus	1.54e-05	0.000151	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—GSTM1—type 2 diabetes mellitus	1.5e-05	0.000147	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—LPL—type 2 diabetes mellitus	1.47e-05	0.000144	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—ADCY5—type 2 diabetes mellitus	1.44e-05	0.000141	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—GPX1—type 2 diabetes mellitus	1.43e-05	0.000141	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—CD36—type 2 diabetes mellitus	1.4e-05	0.000137	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—PPP2CA—type 2 diabetes mellitus	1.38e-05	0.000136	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—MTHFR—type 2 diabetes mellitus	1.32e-05	0.00013	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—PPARA—type 2 diabetes mellitus	1.3e-05	0.000128	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—AGT—type 2 diabetes mellitus	1.26e-05	0.000124	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—CALM1—type 2 diabetes mellitus	1.24e-05	0.000122	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—APOE—type 2 diabetes mellitus	1.23e-05	0.000121	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—APOA1—type 2 diabetes mellitus	1.22e-05	0.00012	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—PPARG—type 2 diabetes mellitus	1.07e-05	0.000105	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—INS—type 2 diabetes mellitus	1.05e-05	0.000103	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—ALB—type 2 diabetes mellitus	9.64e-06	9.48e-05	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—PIK3R1—type 2 diabetes mellitus	9.22e-06	9.07e-05	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—NOS3—type 2 diabetes mellitus	9.22e-06	9.07e-05	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—PTGS2—type 2 diabetes mellitus	8.44e-06	8.3e-05	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—AKT1—type 2 diabetes mellitus	4.24e-06	4.17e-05	CbGpPWpGaD
